Adding Ublituximab to Ibrutinib Improves Relapsed CLL Response Rates

Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia. (Source: CancerNetwork)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2s0Yq7Q
via IFTTT